PUNCH01: Interim results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).Zongren Wang, Junxing Chen, Cheng Luo et al.|Journal of Clinical Oncology|2025Cited by 0